{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.533","value":"0.578"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"}],"units":"Participants"}],"title":"Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.765","value":"1.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"title":"4 hours Post-Dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.","id":"OG000","title":"Obinutuzumab + Venetoclax"}],"paramType":"MEAN","populationDescription":"Analysis population consisted of subjects from whom one or more plasma samples were collected and who had received at least one 400 mg dose of venetoclax. Pre-dose and post-dose data may not come from the same participants. Total number analyzed is therefore higher than the number analyzed for each time point.","reportingStatus":"POSTED","timeFrame":"Pre-venetoclax dose (0 hour) and 4 hours post- venetoclax dose on Day 1 Cycle 4","title":"Plasma Concentrations of Venetoclax","type":"SECONDARY","unitOfMeasure":"μg/mL"}